SCHEMBL2679367

SCHEMBL2679367

CNCc1cccc(Br)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
NPSR1 Q6W5P4 1/20 0.41
MBOAT4 Q96T53 1/20 0.39
CXCR4 P61073 1/20 0.38
PARP1 P09874 1/20 0.38
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
HTR7 P34969 2/20 0.36
HTR1A P08908 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
KDM4E B2RXH2 2/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
FAAH O00519 1/20 0.35
EGFR P00533 1/20 0.35
TP53 P04637 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31330291 1.00 KDM1A (0.47) KDM1AMAOAMAOBNPSR1MBOAT4
SCHEMBL523614 0.84 NPSR1 (0.54) NPSR1CXCR4ALDH1A1KDM4ECYP3A4
SCHEMBL23895431 0.80 KDM1A (0.45) KDM1AMAOAMAOBNPSR1MBOAT4
SCHEMBL8739934 0.80 PARP1 (0.46) KDM1AMAOAMAOBMBOAT4PARP1
SCHEMBL5338175 0.79 KDM1A (0.44) KDM1AMAOAMAOBNPSR1MBOAT4
SCHEMBL2602354 0.77 MAOA (0.43) KDM1AMAOAMAOBNPSR1MBOAT4
SCHEMBL30275482 0.77 KDM1A (0.43) KDM1AMAOAMAOBNPSR1MBOAT4
SCHEMBL7333040 0.77 CXCR4 (0.52) NPSR1CXCR4PARP1KDM4ECYP3A4
SCHEMBL2476858 0.77 SMN1; SMN2 (0.53) KDM1AMAOAMAOBNPSR1MBOAT4
SCHEMBL29791992 0.77 SMN1; SMN2 (0.53) KDM1AMAOAMAOBNPSR1MBOAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103570688-A 2,5-diaminomethylpyrazine compounds, drug compositions, preparation method and use thereof SHANGHAI INST MATERIA MEDICA 2014-02-12 CN claimed
EP-4619406-A1 TRICYCLIC COMPOUNDS Schrödinger, Inc. (US) 2025-09-24 EP disclosed
WO-2025076285-A1 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME DELPHIA THERAPEUTICS, INC. (US) 2025-04-10 WO disclosed
WO-2025042408-A1 METHODS OF TREATING CANCER SCHRÖDINGER, INC. (US) 2025-02-27 WO disclosed
WO-2024107393-A1 TRICYCLIC COMPOUNDS SCHRÖDINGER, INC. (US) 2024-05-23 WO disclosed
US-9328096-B2 Tropomyosin-related kinase inhibitors PFIZER INC. (US) 2016-05-03 US disclosed
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER (US) 2015-11-12 US disclosed
EP-2470012-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2014-11-05 EP disclosed
CN-103570688-A 2,5-diaminomethylpyrazine compounds, drug compositions, preparation method and use thereof SHANGHAI INST MATERIA MEDICA 2014-02-12 CN disclosed
US-8604038-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2013-12-10 US disclosed
EP-2166846-A1 INHIBITORS OF JANUS KINASES Merck Sharp & Dohme Corp. (US) 2010-03-31 EP disclosed
US-20100035897-A1 Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists PROSIDION LIMITED (GB) 2010-02-11 US disclosed
US-20100035897-A1 Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists PROSIDION LIMITED (GB) 2010-02-11 US disclosed
US-20100035897-A1 Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists PROSIDION LIMITED (GB) 2010-02-11 US disclosed
WO-2008156726-A1 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2008-12-24 WO disclosed
WO-2008156726-A1 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2008-12-24 WO disclosed
EP-1838698-A1 PYRIMIDINE DERIVATIVES AS GPCR AGONISTS Prosidion Limited (GB) 2007-10-03 EP disclosed
WO-2006070208-A1 PYRIDINE, PYRIMIDINE AND PYRAZINE DERIVATIVES AS GPCR AGONISTS PROSIDION LTD. (GB) 2006-07-06 WO disclosed
US-7022724-B2 Cognition enhancing derivatives of isoxazole triazoloindane GABA-A α5 receptor subunit ligands MERCK SHARP & DOHME LTD. (GB) 2006-04-04 US disclosed
US-20040058970-A1 Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands MERCK SHARP & DOHME LTD. (GB) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058970-A1 Cognition enhancing derivatives of isoxazole triazoloindane GABA-A alpha 5 receptor subunit ligands GABRA5, GABRA1, GABRB1 KDM1A 2965/4885MAOA 593/4885MAOB 1048/4885
US-20100035897-A1 Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists GPR119, GPR52, GPR65 KDM1A 3675/4885MAOA 2234/4885MAOB 1296/4885
US-20150322043-A1 TROPOMYOSIN-RELATED KINASE INHIBITORS TPM3, MUSK, TPM4 KDM1A 2671/4885MAOA 955/4885MAOB 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.